Genflow Biosciences plc develops gene therapies aimed at extending healthspan and addressing age-related conditions in both humans and canines. The company operates through two main divisions: Human Health, focusing on conditions such as metabolic dysfunction and sarcopenia, and Animal Health, which includes clinical trials for age-related issues in dogs. Genflow utilizes a proprietary SIRT6 gene therapy platform and has transitioned to LNP/mRNA delivery technologies to enhance treatment efficacy. The company is based in the United Kingdom and engages in research and development activities supported by grants and partnerships.